Stock Screener App

무료 -

설치하다

3.765

1.75% 0.045

Fulcrum Therapeutics Inc (FULC)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스

Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66 - Stock Titan

Fulcrum Therapeutics (FULC) director awarded 32,000 stock options - Stock Titan

Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike - Stock Titan

Fulcrum Therapeutics (FULC) director granted 32,000 stock options at $3.66 strike - Stock Titan

[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan

After plunging 21.5% in 4 weeks, here's why the trend might reverse for Fulcrum Therapeutics (FULC) - MSN

Fulcrum Therapeutics | 8-K: Current report - Moomoo

Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcru - GuruFocus

Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan - Stock Titan

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Price to sales forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000 Growth Benchmark - marketscreener.com

Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView

Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit - Yahoo Finance

[144] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan

Fulcrum Therapeutics, Inc. Actuals & Estimates (NASDAQ:FULC) - TradingView

EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan

EcoR1 Capital (FULC) reports shared control of 6.0M shares; 9.0% stake - Stock Titan

Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure - TipRanks

Fulcrum Therapeutics (FULC) details 2026 stockholder voting on directors and key proposals - Stock Titan

Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey

Fulcrum Therapeutics | SCHEDULE 13G: Others - Moomoo

Fulcrum Therapeutics (FULC) Advances 1.8% as Shares Test Resistance Near $4.12Growth ETF - dars.gov.et

Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey

Fulcrum plunges after discontinuing lead program - MSN

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securiti - The National Law Review

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - ACCESS Newswire

2026-06-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | NDAQ:FULC | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire

Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations - NewMediaWire

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewir - The National Law Review

Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Fulcrum Therapeutics Inc (FULC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

2026-06-15 | Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:FULC | Press Release - Stockhouse

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect - ACCESS Newswire

What's going on with Fulcrum Therapeutics stock on Thursday? - MSN

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Fulcrum Therapeutics, Inc. Files Form 8-K Report with SEC – Company Information and Key Details (June 2026) - Minichart

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits

Fulcrum Therapeutics Advances Restructuring with Leadership Changes - TipRanks

Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart - Stock Titan

Fulcrum Therapeutics, Inc. Announces Departure of Greg Tourangeau, Principal Accounting Officer - marketscreener.com

A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs - Yahoo Finance

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Tang entities report 5,451,800‑share stake in Fulcrum (FULC) - Stock Titan

FULC stock crashes as cancer risk forces its only drug program's end - MSN

Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - NewMediaWire

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encour - The National Law Review

Fulcrum Therapeutics, Inc. (FULC) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire

INSM

$112.13

0.86%

RPRX

$57.64

1.24%

ROIV

$36.38

2.68%

MRNA

$78.97

3.14%

ONC

$306.32

1.01%

RVMD

$190.47

0.31%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개